Analyst Price Target is $21.00
▲ +677.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for VYNE Therapeutics in the last 3 months. The average price target is $21.00, with a high forecast of $28.00 and a low forecast of $11.00. The average price target represents a 677.78% upside from the last price of $2.70.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in VYNE Therapeutics. This Buy consensus rating has held steady for over two years.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.